Oral KPV capsules provide direct gut anti-inflammatory effects through intestinal MC1R activation. KPV (Lys-Pro-Val) is a tripeptide derived from the C-terminal sequence of alpha-melanocyte stimulating hormone (alpha-MSH), which is itself a potent endogenous anti-inflammatory neuropeptide. What makes KPV particularly unique among oral peptides is its ability to directly penetrate intestinal epithelial cells — most peptides cannot cross this barrier, but KPV’s small size and specific sequence allow it to enter cells directly and inhibit NF-kB signaling from within. This intracellular mechanism of action makes oral KPV exceptionally effective for gut inflammation, as it can act on both the luminal surface and within the epithelial cells themselves. Research in animal models of colitis has demonstrated significant reductions in intestinal inflammation, mucosal damage scores, and pro-inflammatory cytokine levels with oral KPV administration. It is particularly relevant for conditions including ulcerative colitis, Crohn’s disease, and general intestinal hyperpermeability.